Head-to-head · WeighScore
NewSelf vs Gimme Care
The verdict
Too close to call — both grade 85/100 (B).
NewSelf and Gimme Care land on the same WeighScore, so neither clears the other on our six graded dimensions. NewSelf sits one line higher on the board (#8 vs #9) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NewSelf | Gimme Care |
|---|---|---|
| WeighScore | 85/100 | 85/100 |
| Grade | B | B |
| Scorecard rank | #8 | #9 |
| Semaglutide | $100/mo | $130/mo |
| Tirzepatide | $144/mo | $163/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Editorial | Editorial |
Graded #8 · B
Strengths
- $100 sema / $144 tirz
- All 50 states, LegitScript-verified
- Both molecules
Where it loses points
- Injection-only
- Labs/monitoring detail sparse
- Limited brand history
Graded #9 · B
Strengths
- $130 sema / $163 tirz
- All 50 states, LegitScript-verified
- Both molecules
Where it loses points
- Not the cheapest tier
- Injection-only
- Monitoring detail limited
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.